Structural Dynamics-Driven Discovery of Anticancer and Antimetastatic Effects of Diltiazem and Glibenclamide Targeting Urokinase Receptor.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01663
Abstract: Diltiazem and glibenclamide are commonly used hypotensive and antidiabetic drugs. This study reports the discovery of the potential antitumor and antimetastatic effects of these two drugs using a structural dynamics-driven virtual screening targeting urokinase receptor… read more here.
Keywords: antimetastatic effects; dynamics driven; diltiazem glibenclamide; targeting urokinase ... See more keywords
Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Diabetes Research"
DOI: 10.1155/2017/3232848
Abstract: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide. DN typically manifests by glomerular hyperfiltration and microalbuminuria; then, the disease progresses to impaired glomerular filtration rate, which leads to ESRD. Treatment… read more here.
Keywords: disease; receptor kidney; urokinase receptor; soluble urokinase ... See more keywords
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Antibodies"
DOI: 10.3390/antib8040054
Abstract: A promising molecular target for aggressive cancers is the urokinase receptor (uPAR). A fully human, recombinant antibody that binds uPAR to form a stable complex that blocks uPA-uPAR interactions (2G10) and is internalized primarily through… read more here.
Keywords: drug conjugates; receptor upar; antibody drug; breast cancer ... See more keywords